Bluebird Bio announces updated results demonstrating sustained treatment response in SCD patients treated with LentiGlobin gene therapy

Bluebird Bio announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobinĀ® for SCD, bb1111) gene therapy for sickle cell disease (SCD) following enhancements to the manufacturing protocols and treatment process. The therapy achieves stable production of gene therapy-derived anti-sickling hemoglobin and continued complete resolution of severe vaso-occlusive crisis (VOCs) up to 36 months follow-up (n=2). Data were presented in two oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition ( December 11-14, 2021, Atlanta) an published in the The New England Journal of Medicine (NEJM) (December 12, 2021, DOI: 10.1056/NEJMoa2117175). For more information: press release